Bottom line:
TAVR is proving safe, effective, and durable—even in low-risk patients.
ALIGN-AR opens doors for AR patients with no prior transcatheter options and high surgical risk.
#ACC25

Evolut Low Risk Trial:
TAVR vs. Surgery in patients with severe aortic stenosis + low surgical risk.
5-year outcomes:

TAVR = surgery in death/stroke

Better valve performance with TAVR

Durable quality of life
#ACC25

Why ALIGN-AR matters:
There’s currently NO FDA-approved transcatheter valve for native AR in the US.
This trial could lead to the first dedicated solution for high-risk AR patients.
#ACC25

ALIGN-AR Trial:
First major study focused specifically on high-risk patients with severe aortic regurgitation.
Device: JenaValve Trilogy THV
Result: >95% device success, low 30-day mortality & stroke, improved symptoms.
A game-changer for a previously untreatable group.
#ACC25

Can't wait to read your book @gbiondizoccai.bsky.social
The photo is terrific by the way.

Waiting periods and available places in our rehab centers are obviously a major obstacle.

Was there an associated aneurysm? If yes did the patient present signs of ischaemia related to possible compression?

It's great to see this progress. Happy to be part of this new community.

Thank you.

I just learned about the new platform from a Twitter post. Migration ongoing. It's true that X is becoming too distracting.